European-focused, rare and orphan drug consulting firm, Open Orphan (ORPH) , announced on Monday that they had signed a contract with Carna Bioscience for a first in human clinical pharmacology trial.
Specialising in kinase biology and innovative treatments against cancer and immune disorders, Japanese-based Carna Bioscience will be in partnership with Open Orphan’s Venn Life Sciences.
Venn will provide Carna with expertise ranging from chemistry manufacturing to clinical trial management as well as biometry, legal and regulatory support.
Cathal Friel, Chief Executive of Open Orphan said the contract was “an exciting one,” commenting:
“We are now providing a much broader range of pharmaceutical services and the Venn team have managed to transition the provision of its initial pre-clinical consultancy services to Carna into a formal Phase 1 Clinical Trial.”
Building on several years of collaboration between Venn and Carna, the contract is further evidence of Open Orphan’s strategy to secure long-term partnership contracts to deliver recurring revenues for the business.
"This contract is further evidence of delivering against one of Open Orphan's key objectives, transforming Venn,” added Mr Friel.
“We look forward to delivering the contract for Carna Bioscience and I look forward to announcing more positive news in due course."Follow News & Updates from Open Orphan: